Denali Therapeutics Inc. (DNLI) Operating cash flow 2016–2025
Denali Therapeutics Inc. (DNLI) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$412.6MFY2025 · since FY2016: -$71.9M → -$412.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$412.6M | -18.7% |
| FY2024 | -$347.7M | +2.9% |
| FY2023 | -$358.0M | -46.3% |
| FY2022 | -$244.7M | -15.8% |
| FY2021 | -$211.4M | -150.8% |
| FY2020 | $416.2M | +374.6% |
| FY2019 | -$151.6M | -402.5% |
| FY2018 | $50.1M | +165.4% |
| FY2017 | -$76.6M | -6.6% |
| FY2016 | -$71.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice